Alpha-1 therapy involves the intravenous infusion of purified, human-derived A1AT.7
The goal of therapy is to raise the A1AT levels above the protective threshold of 11 μM (57.2 mg/dL).7
Other treatment options may include:
Clinical data demonstrating the long-term effects of chronic augmentation therapy are not available.
CALL 1-855-ZEMAIRA (1-855-936-2472) or EMAIL Zemairasupport@CSLBehringsales.com